Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.

医学 无容量 内科学 肿瘤科 易普利姆玛 化疗 癌症 免疫疗法
作者
Ian Chau,Yuichiro� Doki,Jaffer A. Ajani,Jianming Xu,Lucjan Wyrwicz,Satoru Motoyama,Takashi Ogata,Hisato Kawakami,Chih‐Hung Hsu,Antoine Adenis,Farid El Hajbi,Maria Di Bartolomeo,Maria Ignez Braghiroli,Eva Holtved,Ioannis Xynos,Xuan Liu,Ming Lei,Kaoru Kondo,Ken Kato,Yuko Kitagawa
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:39 (18_suppl): LBA4001-LBA4001 被引量:72
标识
DOI:10.1200/jco.2021.39.15_suppl.lba4001
摘要

LBA4001 Background: NIVO demonstrated superior overall survival (OS) vs chemo in previously treated patients (pts) with ESCC (ATTRACTION-3). We report OS and progression-free survival (PFS) from CheckMate 648, the first global phase III study to evaluate both an immuno-oncology (I-O)/chemo combination and an I-O/I-O combination in advanced ESCC. Methods: Adults with previously untreated, unresectable advanced, recurrent or metastatic ESCC were enrolled regardless of tumor cell PD-L1 expression. Pts were randomized to NIVO (240 mg Q2W) + chemo (fluorouracil + cisplatin Q4W), NIVO (3 mg/kg Q2W) + IPI (1 mg/kg Q6W), or chemo alone. Primary endpoints for both comparisons were OS and PFS per blinded independent central review (BICR) in pts with tumor cell PD-L1 ≥ 1%. Hierarchically tested secondary endpoints included OS and PFS in all randomized pts. Results: 970 pts were randomized to NIVO + chemo, NIVO + IPI, and chemo arms (49% with tumor cell PD-L1 ≥ 1%). With 13 months (mo) minimum follow-up, NIVO + chemo and NIVO + IPI led to statistically significant improvement in OS vs chemo in pts with tumor cell PD-L1 ≥ 1% and all randomized pts (Table). Statistically significant PFS benefit was also observed for NIVO + chemo vs chemo (HR 0.65 [98.5% CI 0.46–0.92]; P = 0.0023) in pts with tumor cell PD-L1 ≥ 1%. PFS in NIVO + IPI vs chemo in pts with tumor cell PD-L1 ≥ 1% did not meet the prespecified boundary for significance. The objective response rate (per BICR) was 53% (NIVO + chemo), 35% (NIVO + IPI), and 20% (chemo) in pts with tumor cell PD-L1 ≥ 1% and in all randomized pts was 47%, 28%, and 27%, respectively; longer median (95% CI) duration of response was observed vs chemo for pts with tumor cell PD-L1 ≥ 1%: 8.4 (6.9–12.4), 11.8 (7.1–27.4), and 5.7 (4.4–8.7) mo and for all randomized pts: 8.2 (6.9–9.7), 11.1 (8.3–14.0), and 7.1 (5.7–8.2) mo, respectively. No new safety signals were identified (Table). Conclusions: NIVO plus chemo and NIVO plus IPI both demonstrated superior OS vs chemo, along with durable objective responses and acceptable safety, in pts with advanced ESCC, and each represents a potential new 1L treatment option. Clinical trial information: NCT03143153. [Table: see text]

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
寡王一路硕博完成签到,获得积分10
刚刚
刚刚
熊博士完成签到,获得积分10
刚刚
刚刚
林天完成签到,获得积分10
刚刚
splemeth完成签到,获得积分10
刚刚
bai完成签到,获得积分10
1秒前
rainbow5432完成签到 ,获得积分10
1秒前
柠檬水完成签到 ,获得积分10
2秒前
栋汀完成签到,获得积分10
2秒前
黄C发布了新的文献求助10
2秒前
Sherlyn完成签到 ,获得积分10
3秒前
giotto完成签到,获得积分10
3秒前
壮观谷芹完成签到 ,获得积分10
3秒前
虚拟的纸鹤完成签到,获得积分10
3秒前
Wsl发布了新的文献求助10
4秒前
清脆听南发布了新的文献求助10
4秒前
4秒前
4秒前
赵浩宇完成签到,获得积分10
4秒前
zer关注了科研通微信公众号
5秒前
梅夕阳完成签到,获得积分10
7秒前
正文完成签到,获得积分10
7秒前
JIAO完成签到,获得积分10
7秒前
科研通AI6.2的应助被Hunter采纳,获得10
7秒前
和谐续完成签到 ,获得积分10
7秒前
zyw完成签到 ,获得积分10
8秒前
如初发布了新的文献求助10
9秒前
百十余完成签到,获得积分10
9秒前
木木完成签到 ,获得积分10
9秒前
伶俐书蝶完成签到 ,获得积分10
9秒前
兴奋小虾米完成签到 ,获得积分10
9秒前
糟糕的妙海完成签到,获得积分10
10秒前
lll发布了新的文献求助10
10秒前
舒心誉完成签到 ,获得积分10
10秒前
耍酷的汲完成签到,获得积分10
10秒前
熙可檬完成签到 ,获得积分10
10秒前
英勇的愚志完成签到,获得积分10
11秒前
义气的诗霜完成签到,获得积分10
12秒前
C1nderella完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159212
求助须知:如何正确求助?哪些是违规求助? 9554678
关于积分的说明 21720538
捐赠科研通 7748887
什么是DOI,文献DOI怎么找? 3427184
关于科研通互助平台的介绍 2552092
邀请新用户注册赠送积分活动 2471464